Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4555 Assessment of gastric mucosa conditions changes in patients with gastric neuroendocrine neoplasia type 1 during gastroprotective therapy

Introduction: Currently, the incidence of gastric neuroendocrine neoplasia (gNEN) has increased significantly. Most gNEN are developed on the background of chronic atrophic gastritis (about 90%). Despite this, the role of chronic atrophic gastritis treatment (gastroprotective therapy) in dynamic of gNEN remains unexplored.

Conference:

Presenting Author: Konyakhina A

Authors: Konyakhina A, Feidorov I, Salimgereeva D, Petrova A,

Keywords: gNEN, atrophic gastritis, OLGA, rebamipide,

#4243 Role of gastric mucosa evaluation in diagnostic of pancreatic neuroendocrine tumors functional status

Introduction: Accessibility of high-precision imaging dramatically increased detection rate of small asymptomatic pancreatic neuroendocrine tumors (PanNETs). Functioning status is indication for surgical treatment with high perioperative risks, while increased level of NET markers could be associated with gastric mucosa atrophy or intake of proton pump inhibitors (PPI) and nor with tumor secretion.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A,

Keywords: PanNET, chronic atrophic gastritis, marker, OLGA, anti-parietal cell antibodies,

#4154 Gastric mucosa conditions during atrophic gastritis and gastric neuroendocrine neoplasia type 1 (gNEN 1)

Introduction: Worldwide frequency of neuroendocrine tumors increased, which is associated with improved approaches to the diagnosis of chronic diseases of the upper digestive tract. Management of these neoplasms in real clinical practice can be difficult.

Conference:

Presenting Author: Konyakhina A

Authors: Konyakhina A, Feidorov I, Salimgereeva D,

Keywords: gNEN, atrophic gastritis, OLGA, rebamipide,

#3553 Gamma-glutamyltransferase as an indicator of hepatic tumor burden in neuroendocrine tumors

Introduction: In patients with neuroendocrine tumors (NETs) and liver metastasis, elevation of gamma-glutamyltransferase (GGT) is considered to be a sign of hepatic progression. However, there are no data supporting this assumption.

Conference:

Presenting Author: Schmidt B

Authors: Schmidt B, Leiderer M, Amin T, Viol F, Adam G,

Keywords: gamma glutamyltransferase, hepatic tumor burden, neuroendocrine tumor, liver metastasis, biomarker,